These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19934088)

  • 41. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lessons learned from the ONTARGET and TRANSCEND trials.
    Basile J
    Curr Atheroscler Rep; 2009 Sep; 11(5):371-6. PubMed ID: 19664381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Telmisartan in high-risk cardiovascular patients.
    Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Critically appraised article].
    Neumann I; Grassi B
    Rev Med Chil; 2012 Jan; 140(1):117-20. PubMed ID: 22552566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
    Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
    MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
    [No Abstract]   [Full Text] [Related]  

  • 48. Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
    Weber M
    J Hypertens Suppl; 2009 Jul; 27(5):S9-14. PubMed ID: 19587555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.
    Müller P; Kazakov A; Semenov A; Jagoda P; Friedrich EB; Böhm M; Laufs U
    J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):87-93. PubMed ID: 22368266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.
    Petrovic I; Petrovic D; Vukovic N; Zivanovic B; Dragicevic J; Vasiljevic Z; Babic R
    J Int Med Res; 2005; 33 Suppl 1():39A-49A. PubMed ID: 16222899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The ONTARGET trial].
    Verdecchia P; Terrosu P
    G Ital Cardiol (Rome); 2009 Feb; 10(2):67-72. PubMed ID: 19348142
    [No Abstract]   [Full Text] [Related]  

  • 53. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular protection: a breakthrough for high-risk patients?
    Ferrari R
    J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected].
    Einecke D
    MMW Fortschr Med; 2008 Sep; 150(38):14, 16. PubMed ID: 18983047
    [No Abstract]   [Full Text] [Related]  

  • 56. Renin-angiotensin blockade and kidney disease.
    Sarafidis PA; Bakris GL
    Lancet; 2008 Aug; 372(9638):511-2. PubMed ID: 18707969
    [No Abstract]   [Full Text] [Related]  

  • 57. Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?
    Hankey GJ; ; ;
    Stroke; 2003 Feb; 34(2):354-6. PubMed ID: 12574534
    [No Abstract]   [Full Text] [Related]  

  • 58. Telmisartan for the management of patients at high cardiovascular risk.
    Ruilope LM
    Curr Med Res Opin; 2011 Aug; 27(8):1673-82. PubMed ID: 21718097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lessons from ONTARGET.
    Berlaimont V; Billiouw JM; Brohet C; Dupont AG; Gazagnes MD; Heller F; Krzesinski JM; Missault L; Persu A; Piérard L; Rottiers R; Vanhooren G; Van Mieghem W; Vervaet P; Herman AG
    Acta Clin Belg; 2008; 63(3):142-51. PubMed ID: 18714845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [No advantage of the combination of ACE-inhibition and angiotensin receptor blockade in patients with high cardiovascular risk].
    van den Meiracker AH
    Ned Tijdschr Geneeskd; 2008 Jun; 152(24):1358-60. PubMed ID: 18664211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.